196-OR: A Meal Detection Algorithm for the Artificial Pancreas: A Randomized Controlled Clinical Trial in Adolescents with Type 1 Diabetes

EMILIE PALISAITIS; ANAS EL FATHI; AHMAD HAIDAR; JULIA E. VON OETTINGEN; LAURENT LEGAULT

doi:10.2337/db20-196-OR

Oral Presentations: Clinical Diabetes/Therapeutics

196-OR: A Meal Detection Algorithm for the Artificial Pancreas: A Randomized Controlled Clinical Trial in Adolescents with Type 1 Diabetes

EMILIE PALISAITIS,
ANAS EL FATHI,
AHMAD HAIDAR,
JULIA E. VON OETTINGEN and
LAURENT LEGAULT

Montreal, QC, Canada

Diabetes 2020 Jun; 69(Supplement 1): -. https://doi.org/10.2337/db20-196-OR

Abstract

Background: People with type 1 diabetes occasionally forget to announce meals to their insulin pump, which degrades glycemic control. We have developed a meal detection algorithm for the artificial pancreas (AP) that detects unannounced meals and delivers boluses.

Methods: We conducted a randomized crossover trial in adolescents aged 12-18 years with type 1 diabetes. We compared (i) CSII, (ii) AP, and (iii) AP with a meal detection algorithm (AP+MDA) in controlling post-prandial glucose levels after a meal without a bolus. Participants underwent three 9-hour interventions which included breakfast with a CHO-matched bolus and lunch without a bolus. The primary outcome was the iAUC of the glucose excursions from the start of lunch to 4 hours post-lunch.

Results: 11 participants (mean age 14.9±1.3, HbA1c 8.3±0.6%) were included. Compared to CSII, AP+MDA decreased iAUC from the start of lunch to 4 hours post-lunch from 24±9.5 h.mmol/L to 15±8 h.mmol/L (p=0.03). The AP+MDA reduced time > 10 mmol/L after the missed bolus by -21.6% (IQR: [-39.4- -3.8]) compared to CSII (p=0.02). The mean meal detection time was 41.8±16 minutes after meal consumption.

Conclusions: The AP+MDA successfully decreased iAUC after an unannounced meal in adolescents with type 1 diabetes. Longer and larger studies are needed to evaluate the efficacy of this meal detection algorithm in real-world settings.

Disclosure E. Palisaitis: None. A. El Fathi: None. A. Haidar: Consultant; Self; Eli Lilly and Company. Research Support; Self; Dexcom, Inc., Eli Lilly and Company. J.E. von Oettingen: None. L. Legault: Advisory Panel; Self; Dexcom, Inc., Lilly Diabetes. Research Support; Self; AstraZeneca K.K., Merck & Co., Inc., Sanofi-Aventis. Other Relationship; Self; Lilly Diabetes.

http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.